{"config":{"lang":["en"],"min_search_length":3,"prebuild_index":false,"separator":"[\\s\\-]+"},"docs":[{"location":"","text":"\u8734\u8734\u5167\u79d1 tags: tutorials \u96fb\u5b50\u66f8\u5e73\u53f0 Washinton Manual\u7dda\u4e0a\u96fb\u5b50\u66f8 On call principle\u7dda\u4e0a\u96fb\u5b50\u66f8 Website \u51a0\u4f51 Note Radiology Anki PharmWiki \u67d0\u85e5\u5e2b\u7684ppt NEJM Residnet 360 Knowledge+ ACLS Megacode by Dr.\u9ec3 ACLS \u85e5\u7269.pdf","title":"\u8734\u8734\u5167\u79d1"},{"location":"#_1","text":"","title":"\u8734\u8734\u5167\u79d1"},{"location":"#tags-tutorials","text":"","title":"tags: tutorials"},{"location":"#_2","text":"Washinton Manual\u7dda\u4e0a\u96fb\u5b50\u66f8 On call principle\u7dda\u4e0a\u96fb\u5b50\u66f8","title":"\u96fb\u5b50\u66f8\u5e73\u53f0"},{"location":"#website","text":"\u51a0\u4f51 Note Radiology Anki PharmWiki \u67d0\u85e5\u5e2b\u7684ppt","title":"Website"},{"location":"#nejm","text":"Residnet 360 Knowledge+","title":"NEJM"},{"location":"#acls","text":"Megacode by Dr.\u9ec3 ACLS \u85e5\u7269.pdf","title":"ACLS"},{"location":"01-%E5%BF%83/01-01-Electrocardiography/","text":"1. Electrocardiography Approach (*a systematic approach is *)** \u2022 Rate (? tachy, brady) and rhythm (? relationship between P and QRS) \u2022 Intervals (PR, QRS, QT) and axis (? LAD or RAD) \u2022 Chamber abnormality (? LAA and/or RAA, ? LVH and/or RVH) \u2022 QRST changes (? Q waves, poor R-wave progression V1\u2013V6, ST \u2191/\u2193 or T-wave \u0394s) Figure 1-1\u2002QRS axis Left axis deviation (LAD) \u2022 Definition : axis beyond \u201330\u00b0 (S > R in lead II) \u2022 Etiologies : LVH, LBBB, inferior MI, WPW \u2022 Left anterior fascicular block : LAD (\u201345 to \u201390\u00b0) and qR in aVL and QRS <120 msec and no other cause of LAD (eg, IMI) Right axis deviation (RAD) \u2022 Definition : axis beyond +90\u00b0 (S > R in lead I) \u2022 Etiologies : RVH, PE, COPD (usually not > +110\u00b0), septal defects, lateral MI, WPW \u2022 Left posterior fascicular block : RAD (90\u2013180\u00b0) and rS in I & aVL and qR in III & aVF and QRS <120 msec and no other cause of RAD Prolonged QT interval (*NEJM* 2008;358:169; www.torsades.org ) \u2022 QT measured from beginning of QRS complex to end of T wave (measure longest QT) \u2022 QT varies w/ HR \u2192 correct w/ Bazett formula: QTc = QT/\u221aRR (in sec), formula inaccurate at very high and low HR (nl QTc <440 msec \u7537 and <460 msec \u5973) \u2022 QT prolongation a/w \u2191 risk TdP (esp. >500 msec); perform baseline/serial ECGs if using QT prolonging meds, no estab guidelines for stopping Rx if QT prolongs \u2022 Etiologies: Antiarrhythmics : class Ia (procainamide, disopyramide), class III (amiodarone, sotalol) Psych drugs : antipsychotics (phenothiazines, haloperidol, atypicals), Li, ? SSRI, TCA Antimicrobials : macrolides, quinolones, azoles, pentamidine, atovaquone, atazanavir Other : antiemetics (droperidol, 5-HT3 antagonists), alfuzosin, methadone, ranolazine Electrolyte disturbances : hypoCa (nb, hyperCa a/w \u2193 QT), ? hypoK, ? hypoMg Autonomic dysfxn : ICH (deep TWI), stroke, carotid endarterectomy, neck dissection Congenital (long QT syndrome): K, Na, Ca channelopathies ( Circ 2013;127:126) Misc : CAD, CMP, bradycardia, high-grade AVB, hypothyroidism, hypothermia, BBB","title":"1. Electrocardiography"},{"location":"01-%E5%BF%83/01-01-Electrocardiography/#1-electrocardiography","text":"","title":"1. Electrocardiography"},{"location":"01-%E5%BF%83/01-01-Electrocardiography/#approach-a-systematic-approach-is","text":"\u2022 Rate (? tachy, brady) and rhythm (? relationship between P and QRS) \u2022 Intervals (PR, QRS, QT) and axis (? LAD or RAD) \u2022 Chamber abnormality (? LAA and/or RAA, ? LVH and/or RVH) \u2022 QRST changes (? Q waves, poor R-wave progression V1\u2013V6, ST \u2191/\u2193 or T-wave \u0394s) Figure 1-1\u2002QRS axis Left axis deviation (LAD) \u2022 Definition : axis beyond \u201330\u00b0 (S > R in lead II) \u2022 Etiologies : LVH, LBBB, inferior MI, WPW \u2022 Left anterior fascicular block : LAD (\u201345 to \u201390\u00b0) and qR in aVL and QRS <120 msec and no other cause of LAD (eg, IMI) Right axis deviation (RAD) \u2022 Definition : axis beyond +90\u00b0 (S > R in lead I) \u2022 Etiologies : RVH, PE, COPD (usually not > +110\u00b0), septal defects, lateral MI, WPW \u2022 Left posterior fascicular block : RAD (90\u2013180\u00b0) and rS in I & aVL and qR in III & aVF and QRS <120 msec and no other cause of RAD Prolonged QT interval (*NEJM* 2008;358:169; www.torsades.org ) \u2022 QT measured from beginning of QRS complex to end of T wave (measure longest QT) \u2022 QT varies w/ HR \u2192 correct w/ Bazett formula: QTc = QT/\u221aRR (in sec), formula inaccurate at very high and low HR (nl QTc <440 msec \u7537 and <460 msec \u5973) \u2022 QT prolongation a/w \u2191 risk TdP (esp. >500 msec); perform baseline/serial ECGs if using QT prolonging meds, no estab guidelines for stopping Rx if QT prolongs \u2022 Etiologies: Antiarrhythmics : class Ia (procainamide, disopyramide), class III (amiodarone, sotalol) Psych drugs : antipsychotics (phenothiazines, haloperidol, atypicals), Li, ? SSRI, TCA Antimicrobials : macrolides, quinolones, azoles, pentamidine, atovaquone, atazanavir Other : antiemetics (droperidol, 5-HT3 antagonists), alfuzosin, methadone, ranolazine Electrolyte disturbances : hypoCa (nb, hyperCa a/w \u2193 QT), ? hypoK, ? hypoMg Autonomic dysfxn : ICH (deep TWI), stroke, carotid endarterectomy, neck dissection Congenital (long QT syndrome): K, Na, Ca channelopathies ( Circ 2013;127:126) Misc : CAD, CMP, bradycardia, high-grade AVB, hypothyroidism, hypothermia, BBB","title":"Approach (*a systematic approach is *)**"},{"location":"01-%E5%BF%83/01-02-Chest-Pain/","text":"2. Chest Pain","title":"2. Chest Pain"},{"location":"01-%E5%BF%83/01-02-Chest-Pain/#2-chest-pain","text":"","title":"2. Chest Pain"},{"location":"01-%E5%BF%83/01-03-Noninvasive-Evaluation-of-CAD/","text":"3. Noninvasive Evaluation of CAD","title":"3. Noninvasive Evaluation of CAD"},{"location":"01-%E5%BF%83/01-03-Noninvasive-Evaluation-of-CAD/#3-noninvasive-evaluation-of-cad","text":"","title":"3. Noninvasive Evaluation of CAD"},{"location":"01-%E5%BF%83/01-04-Coronary-Angiography-and-Revascularization/","text":"4. Coronary Angiography and Revascularization","title":"4. Coronary Angiography and Revascularization"},{"location":"01-%E5%BF%83/01-04-Coronary-Angiography-and-Revascularization/#4-coronary-angiography-and-revascularization","text":"","title":"4. Coronary Angiography and Revascularization"},{"location":"01-%E5%BF%83/01-05-Acute-Coronary-Syndromes/","text":"5. Acute Coronary Syndromes","title":"5. Acute Coronary Syndromes"},{"location":"01-%E5%BF%83/01-05-Acute-Coronary-Syndromes/#5-acute-coronary-syndromes","text":"","title":"5. Acute Coronary Syndromes"},{"location":"01-%E5%BF%83/01-06-PA-Catheter-and-Tailored-Therapy/","text":"6. PA Catheter and Tailored Therapy","title":"6. PA Catheter and Tailored Therapy"},{"location":"01-%E5%BF%83/01-06-PA-Catheter-and-Tailored-Therapy/#6-pa-catheter-and-tailored-therapy","text":"","title":"6. PA Catheter and Tailored Therapy"},{"location":"01-%E5%BF%83/01-07-Heart-Failure/","text":"7. Heart Failure","title":"7. Heart Failure"},{"location":"01-%E5%BF%83/01-07-Heart-Failure/#7-heart-failure","text":"","title":"7. Heart Failure"},{"location":"01-%E5%BF%83/01-08-Cardiomyopathies/","text":"8. Cardiomyopathies","title":"8. Cardiomyopathies"},{"location":"01-%E5%BF%83/01-08-Cardiomyopathies/#8-cardiomyopathies","text":"","title":"8. Cardiomyopathies"},{"location":"01-%E5%BF%83/01-09-Valvular-Heart-Disease/","text":"","title":"01 09 Valvular Heart Disease"},{"location":"01-%E5%BF%83/01-10.Pericardial-Disease/","text":"","title":"01 10.Pericardial Disease"},{"location":"01-%E5%BF%83/01-11.Hypertension/","text":"","title":"01 11.Hypertension"},{"location":"01-%E5%BF%83/01-12.Aortic-Aneurysms/","text":"","title":"01 12.Aortic Aneurysms"},{"location":"01-%E5%BF%83/01-13.Acute-Aortic-Syndromes/","text":"","title":"01 13.Acute Aortic Syndromes"},{"location":"01-%E5%BF%83/01-14.Arrhythmias/","text":"","title":"01 14.Arrhythmias"},{"location":"01-%E5%BF%83/01-15.Atrial-Fibrillation/","text":"","title":"01 15.Atrial Fibrillation"},{"location":"01-%E5%BF%83/01-16.Syncope/","text":"","title":"01 16.Syncope"},{"location":"01-%E5%BF%83/01-17.Cardiac-Rhythm-Management-Devices/","text":"","title":"01 17.Cardiac Rhythm Management Devices"},{"location":"01-%E5%BF%83/01-18.Cardiac-Risk-Assessment-for-Noncardiac-Surgery/","text":"","title":"01 18.Cardiac Risk Assessment for Noncardiac Surgery"},{"location":"01-%E5%BF%83/01-19.Peripheral-Artery-Disease/","text":"","title":"01 19.Peripheral Artery Disease"},{"location":"02-%E8%82%BA/02-01-Dyspnea-Pulmonary/","text":"","title":"02 01 Dyspnea Pulmonary"},{"location":"02-%E8%82%BA/02-02-Function-Tests/","text":"","title":"02 02 Function Tests"},{"location":"02-%E8%82%BA/02-03-Asthma/","text":"","title":"02 03 Asthma"},{"location":"02-%E8%82%BA/02-04-Anaphylaxis/","text":"","title":"02 04 Anaphylaxis"},{"location":"02-%E8%82%BA/02-05-Chronic-Obstructive/","text":"","title":"02 05 Chronic Obstructive"},{"location":"02-%E8%82%BA/02-06-Pulmonary-Disease/","text":"","title":"02 06 Pulmonary Disease"},{"location":"02-%E8%82%BA/02-07-Solitary-Pulmonary-Nodule/","text":"","title":"02 07 Solitary Pulmonary Nodule"},{"location":"02-%E8%82%BA/02-08.Hemoptysis/","text":"","title":"02 08.Hemoptysis"},{"location":"02-%E8%82%BA/02-09-Bronchiectasis/","text":"","title":"02 09 Bronchiectasis"},{"location":"02-%E8%82%BA/02-10-Cystic-Fibrosis/","text":"","title":"02 10 Cystic Fibrosis"},{"location":"02-%E8%82%BA/02-11-Interstitial-Lung-Disease/","text":"","title":"02 11 Interstitial Lung Disease"},{"location":"02-%E8%82%BA/02-12-Pleural-Effusion/","text":"","title":"02 12 Pleural Effusion"},{"location":"02-%E8%82%BA/02-13-Venous-Thromboembolism/","text":"","title":"02 13 Venous Thromboembolism"},{"location":"02-%E8%82%BA/02-14-Pulmonary-Hypertension/","text":"","title":"02 14 Pulmonary Hypertension"},{"location":"02-%E8%82%BA/02-15-Respiratory-Failure/","text":"see the link","title":"02 15 Respiratory Failure"},{"location":"02-%E8%82%BA/02-16-Mechanical-Ventilation/","text":"","title":"02 16 Mechanical Ventilation"},{"location":"02-%E8%82%BA/02-17-Acute-Respiratory-Distress-Syndrome/","text":"","title":"02 17 Acute Respiratory Distress Syndrome"},{"location":"02-%E8%82%BA/02-18-Sepsis-and-Shock/","text":"SEPSIS AND SHOCK Definitions Sepsis Life-threatening organ dysfxn (SOFA \u2206 \u22652) due to infection Quick SOFA (qSOFA): \u22652 of the following: RR \u226522, \u2206MS, SBP \u2264100 mmHg Septic shock Sepsis-induced circulatory and cellular/metabolic abnormalities severe enough to \u2191 mortality; hypotension requiring pressors for MAP \u226565 and lactate >2 despite adequate fluid resuscitation Sequential Organ Failure Assessment (SOFA): \u2191 points for worsening organ dysfxn: respiration (\u2193 P:F ratio); coag (\u2193 plt); liver (\u2191 bili); CV (\u2193 MAP or \u2191 pressors); CNS (\u2193 GCS); renal (\u2191 Cr or \u2193 UOP)","title":"SEPSIS AND SHOCK"},{"location":"02-%E8%82%BA/02-18-Sepsis-and-Shock/#sepsis-and-shock","text":"","title":"SEPSIS AND SHOCK"},{"location":"02-%E8%82%BA/02-18-Sepsis-and-Shock/#definitions","text":"Sepsis Life-threatening organ dysfxn (SOFA \u2206 \u22652) due to infection Quick SOFA (qSOFA): \u22652 of the following: RR \u226522, \u2206MS, SBP \u2264100 mmHg Septic shock Sepsis-induced circulatory and cellular/metabolic abnormalities severe enough to \u2191 mortality; hypotension requiring pressors for MAP \u226565 and lactate >2 despite adequate fluid resuscitation","title":"Definitions"},{"location":"02-%E8%82%BA/02-18-Sepsis-and-Shock/#sequential-organ-failure-assessment-sofa","text":"\u2191 points for worsening organ dysfxn: respiration (\u2193 P:F ratio); coag (\u2193 plt); liver (\u2191 bili); CV (\u2193 MAP or \u2191 pressors); CNS (\u2193 GCS); renal (\u2191 Cr or \u2193 UOP)","title":"Sequential Organ Failure Assessment (SOFA):"},{"location":"02-%E8%82%BA/02-19-Toxicology/","text":"","title":"02 19 Toxicology"},{"location":"02-%E8%82%BA/02-20-Lung-Transplant/","text":"","title":"02 20 Lung Transplant"},{"location":"03-%E8%82%9D%E8%85%B8/03-01-Esophageal-and-Gastric-Disorders/","text":"","title":"03 01 Esophageal and Gastric Disorders"},{"location":"03-%E8%82%9D%E8%85%B8/03-02-Gastrointestinal-Bleeding/","text":"","title":"03 02 Gastrointestinal Bleeding"},{"location":"03-%E8%82%9D%E8%85%B8/03-03-Diarrhea/","text":"","title":"03 03 Diarrhea"},{"location":"03-%E8%82%9D%E8%85%B8/03-04-Dysmotility/","text":"","title":"03 04 Dysmotility"},{"location":"03-%E8%82%9D%E8%85%B8/03-05-Disorders-of-the-Colon/","text":"","title":"03 05 Disorders of the Colon"},{"location":"03-%E8%82%9D%E8%85%B8/03-06-Inflammatory-Bowel-Disease/","text":"","title":"03 06 Inflammatory Bowel Disease"},{"location":"03-%E8%82%9D%E8%85%B8/03-07-Intestinal-Ischemia/","text":"","title":"03 07 Intestinal Ischemia"},{"location":"03-%E8%82%9D%E8%85%B8/03-08-Pancreatitis/","text":"","title":"03 08 Pancreatitis"},{"location":"03-%E8%82%9D%E8%85%B8/03-09-Abnormal-Liver-Tests/","text":"","title":"03 09 Abnormal Liver Tests"},{"location":"03-%E8%82%9D%E8%85%B8/03-10-Hepatitis/","text":"","title":"03 10 Hepatitis"},{"location":"03-%E8%82%9D%E8%85%B8/03-11-Acute-Liver-Failure/","text":"","title":"03 11 Acute Liver Failure"},{"location":"03-%E8%82%9D%E8%85%B8/03-12-Cirrhosis/","text":"","title":"03 12 Cirrhosis"},{"location":"03-%E8%82%9D%E8%85%B8/03-13-Hepatic-Vascular-Disease/","text":"","title":"03 13 Hepatic Vascular Disease"},{"location":"03-%E8%82%9D%E8%85%B8/03-14-Ascites/","text":"","title":"03 14 Ascites"},{"location":"03-%E8%82%9D%E8%85%B8/03-15-Biliary-Tract-Disease/","text":"","title":"03 15 Biliary Tract Disease"},{"location":"04-%E8%85%8E/04-01-Acid-Base-Disturbances/","text":"","title":"04 01 Acid Base Disturbances"},{"location":"04-%E8%85%8E/04-02-Sodium-and-Water-Homeostasis/","text":"","title":"04 02 Sodium and Water Homeostasis"},{"location":"04-%E8%85%8E/04-03-Potassium-Homeostasis/","text":"","title":"04 03 Potassium Homeostasis"},{"location":"04-%E8%85%8E/04-04-Renal-Failure/","text":"CHRONIC KIDNEY DISEASE (CKD) Definition and etiologies (Lancet 2012;379:165; JAMA 2015;313:837) \u2022 GFR <60 for \u22653 mo and/or kidney damage (albuminuria, structural abnormality) \u2022 Prevalence 15% in U.S. \u2022 Albuminuria predicts all-cause & CV mortality, CKD progression (NEJM 2004;351:1296) \u2022 Cr poor estimate of GFR, use equation (www.kidney.org/professionals/KDOQI/gfr_calculator.cfm) CKD-EPI preferred over MDRD because less likely to underestimate at normal GFRs cystatin-C\u2013based formulae perform better than Cr-based (NEJM 2012;367:20) \u2022 Etiologies: DM (45%), HTN/RAS (27%), glomerular (10%), interstitial (5%), PKD (2%) (NEJM 2008;359:1477; AJKD 2019;73:A7), congenital, drugs, myeloma (JAMA 2009;302:1179), repeated insults (eg, Mesoamerican nephropathy AJKD 2018;72:469) \u2022 Progression to ESRD: kidney failure risk equation (JAMA 2016;315:164)","title":"04 04 Renal Failure"},{"location":"04-%E8%85%8E/04-04-Renal-Failure/#chronic-kidney-disease-ckd","text":"Definition and etiologies (Lancet 2012;379:165; JAMA 2015;313:837) \u2022 GFR <60 for \u22653 mo and/or kidney damage (albuminuria, structural abnormality) \u2022 Prevalence 15% in U.S. \u2022 Albuminuria predicts all-cause & CV mortality, CKD progression (NEJM 2004;351:1296) \u2022 Cr poor estimate of GFR, use equation (www.kidney.org/professionals/KDOQI/gfr_calculator.cfm) CKD-EPI preferred over MDRD because less likely to underestimate at normal GFRs cystatin-C\u2013based formulae perform better than Cr-based (NEJM 2012;367:20) \u2022 Etiologies: DM (45%), HTN/RAS (27%), glomerular (10%), interstitial (5%), PKD (2%) (NEJM 2008;359:1477; AJKD 2019;73:A7), congenital, drugs, myeloma (JAMA 2009;302:1179), repeated insults (eg, Mesoamerican nephropathy AJKD 2018;72:469) \u2022 Progression to ESRD: kidney failure risk equation (JAMA 2016;315:164)","title":"CHRONIC KIDNEY DISEASE (CKD)"},{"location":"04-%E8%85%8E/04-05-Glomerular-Disease/","text":"","title":"04 05 Glomerular Disease"},{"location":"04-%E8%85%8E/04-06-Urinalysis/","text":"","title":"04 06 Urinalysis"},{"location":"04-%E8%85%8E/04-07-Nephrolithiasis/","text":"","title":"04 07 Nephrolithiasis"},{"location":"04-%E8%85%8E/04-08-Acid-Base-Disturbances/","text":"","title":"04 08 Acid Base Disturbances"},{"location":"04-%E8%85%8E/04-09-Sodium-and-Water-Homeostasis/","text":"","title":"04 09 Sodium and Water Homeostasis"},{"location":"04-%E8%85%8E/04-10-Potassium-Homeostasis/","text":"","title":"04 10 Potassium Homeostasis"},{"location":"04-%E8%85%8E/04-11-Renal-Failure/","text":"","title":"04 11 Renal Failure"},{"location":"04-%E8%85%8E/04-12-Glomerular-Disease/","text":"","title":"04 12 Glomerular Disease"},{"location":"04-%E8%85%8E/04-13-Urinalysis/","text":"","title":"04 13 Urinalysis"},{"location":"04-%E8%85%8E/04-14-Nephrolithiasis/","text":"","title":"04 14 Nephrolithiasis"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/","text":"Anemia \u2193 in RBC mass: Hct <41% or Hb <13.5 g/dL (men); Hct <36% or Hb <12 g/dL (women) Clinical manifestations Symptoms: \u2193 O 2 delivery \u2192 fatigue, exertional dyspnea, angina (if CAD) Signs: pallor (mucous membranes, palmar creases), tachycardia, orthostatic hypotension Other findings: jaundice (hemolysis), splenomegaly (thalassemia, neoplasm, chronic hemolysis), petechiae/purpura (bleeding disorder), glossitis (iron, folate, vitamin B 12 defic.), koilonychia (iron defic.), neurologic abnormalities (B 12 defic.) Diagnostic evaluation History: bleeding, systemic illness, drugs, exposures, alcohol, diet (including pica), FHx CBC w/ diff.; RBC params incl. retics, MCV (nb, mixed disorder can \u2192 nl MCV), RDW Reticulocyte index (RI) = [reticulocyte count \u00d7 (Pt\u2019s Hct/nl Hct)]/maturation factor maturation factors for a given Hct: 45% = 1, 35% = 1.5, 25% = 2, 20% = 2.5 RI >2% \u2192 adequate marrow response; RI <2% \u2192 hypoproliferation Peripheral smear: select area where roughly \u2153 RBCs touch each other; \u4ff6 RBC size, shape, inclusions (see \u201cAppendix\u201d & \u201cPeripheral Smear\u201d), WBC morphology, plt count Additional labs as indicated: hemolysis labs (if RI >2%, see below), iron/TIBC, ferritin, folate, B 12 , LFTs, BUN & Cr, TFTs, Hb electrophoresis, enzyme/gene mutation screens \u2022 Bone marrow (BM) aspirate and biopsy (bx) with cytogenetics as indicated Figure 5-1 Approach to anemia and common causes MICROCYTIC ANEMIAS Figure 5-2 Approach to microcytic anemias (NEJM 2014;371:1324) Iron deficiency (NEJM 2015;372:1832; Lancet 2016;387:907) \u2193 marrow iron & depleted body iron stores \u2192 \u2193 heme synthesis \u2192 microcytosis \u2192 anemia Special clinical manifestations: angular cheilosis, atrophic glossitis, pica (consumption of nonnutritive substances such as ice, clay), koilonychia (nail spooning) Plummer-Vinson syndrome (iron deficiency anemia, esophageal web & atrophic glossitis) Etiologies: chronic bleeding (GI\u2014incl. cancer, menstrual, parasites, NSAIDs, etc.), \u2193 supply (malnutrition; \u2193 absorp. due to celiac sprue, Crohn\u2019s, \u2191 gastric pH, subtotal gastrectomy), \u2191 demand (preg; Blood 2017;129:940). Iron-refractory iron-defic. anemia (IRIDA; rare genetic disorder due to hepcidin dysregulation; Nat Genet 2008;40:569). Diagnosis (eval ideally before Rx): \u2193 Fe, \u2191 TIBC, \u2193 ferritin (esp. <15), \u2193 transferrin sat (Fe/TIBC; esp. <15%), \u2191 soluble transferrin receptor; \u2191 plt. Unless hx c/w other etiology, initiate workup for GIB, incl. H. pylori serology. ? Celiac labs (antiTTG, antigliadin, anti-endomysial Abs). Cytogenetics & molecular testing as indicated. Treatment: oral Fe tid (~6 wks to correct anemia; ~6 mo to replete Fe stores; nb, oral Fe does not give \u0370 Hemoccult). In excessive/persistent GI losses or dialysis, cancer, CHF, or prior to Epo Rx, IV iron (Fe-sucrose, -gluconate, -dextran) should be considered. Thalassemias (Lancet 2018;391:155) \u2193 synthesis of \u03b1- or \u03b2-globin chains of Hb \u2192 \u2260 subunits \u2192 destruction of RBCs and erythroid precursors; \u0127 anemia from hemolysis and ineffective erythropoiesis \u03b1-thalassemia (NEJM 2014;371:1908): deletions in \u03b1-globin gene complex (nl 4 \u03b1 genes), seen w/ Southeast Asian, Mediterranean, African, Middle East ancestry 3 \u03b1 \u2192 \u03b1-thal-2 trait = silent carrier; 2 \u03b1 \u2192 \u03b1-thal-1 trait or \u03b1thal minor = mild anemia 1 \u03b1 \u2192 HbH (\u03b2 4 ) disease = severe anemia, hemolysis, and splenomegaly 0 \u03b1 genes \u2192 Hb Barts (\u03b3 4 ) = intrauterine hypoxia and hydrops fetalis \u03b2-thalassemia: mutations in \u03b2-globin gene \u2192 absent or \u2193 gene product seen w/ Mediterranean (espec. Greek or Italian), African, or Asian ancestry 1 mutated \u03b2 gene \u2192 thal minor (or trait) = mild anemia (no transfusions) 2 mutated \u03b2 genes \u2192 thal intermedia (occasional transfusions) or thal major (= Cooley\u2019s anemia; transfusion dependent) depending on severity of mutations Special clinical manifestations: chipmunk facies, pathologic fractures, hepatosplenomegaly (due to extramedullary hematopoiesis), high-output CHF, bilirubin gallstones, Fe overload Dx: MCV <70, normal Fe, ferritin, MCV/RBC count <13 [Mentzer Index, 60% Se, 98% Sp; (Ann Hem 2007;86:486)], \u00b1 \u2191 retics, basophilic stippling; Hb electrophoresis: \u2191 HbA 2 (\u03b1 2 \u03b4 2 ) in \u03b2-thal; normal pattern in \u03b1-thal trait, \u0127 PCR or supravital stain for dx Treatment: folate; transfusions + Fe chelator [either deferoxamine (IV) or deferasirox (PO)]; ? splenectomy if \u226550% \u2191 in transfusions; consider allo-HSCT in children w/ severe \u03b2thal; gene therapy in development (NEJM 2018;378:1479) Anemia of chronic inflammation (see below) Sideroblastic anemia Defective heme biosynthesis within RBC precursors Etiologies: hereditary/X-linked (ALAS2 mutations), idiopathic, MDS-RARS, reversible (alcohol, lead, isoniazid, chloramphenicol, copper deficiency, hypothermia) Special clinical manifestations: hepatosplenomegaly, iron overload syndromes Dx: social, work & TB hx; can be micro-, normo-, or macrocytic; variable populations of hypochromic RBCs; \u2191 Fe, nl TIBC, \u2191 ferritin, basophilic stippling, RBC Pappenheimer bodies (Fecontaining inclusions), ring sideroblasts (w/ iron-laden mitochondria) in BM Treatment: treat reversible causes; trial of pyridoxine, supportive transfusions for severe anemia with chelation therapy; highdose pyridoxine for some hereditary cases NORMOCYTIC ANEMIAS Pancytopenia (see below) Anemia of chronic inflammation (ACI; NEJM 2012;366:4) \u2193 RBC production due to impaired iron utilization and functional iron deficiency from \u2191 hepcidin; cytokines (IL-6, TNF-\u03b1) cause \u2193 Epo responsiveness/production Etiologies: autoimmune disorders, chronic infection, inflammation, HIV, malignancy Dx: \u2193 Fe, \u2193 TIBC (usually normal or low transferrin sat), \u00b1 \u2191 ferritin; usually normochromic, normocytic (~70% of cases) but can be microcytic if prolonged Coexisting iron deficiency common. Dx clues include \u2193 serum ferritin levels, absence of iron staining on BM bx, \u0370 response to a trial of oral iron and/or \u2191 soluble transferrin receptor/ferritin index (Am J Clin Pathol 2012;138:642). Treatment: treat underlying disease \u00b1 iron and/or erythropoiesisstimulating agent (ESA; eg, Epo). Iron if ferritin <100 or Fe/TIBC <20%. Consider ESA if Epo <500. Avoid ESA in cancer if treatment goal is cure (Lancet 2009;373:1532). Transfuse PRBCs only if symptomatic & insufficient time to wait for response to Epo or underlying disease Rx. Anemias of other chronic disorders Anemia of chronic kidney disease: \u2193 Epo; treat w/ Epo (see \u201cChronic Kidney Disease\u201d) Endocrine deficiencies: hypometabolism and \u2193 O 2 demand with thyroid, pituitary, adrenal, or parathyroid disease \u2192 \u2193 Epo; can be normocytic or macrocytic Sideroblastic anemia (see above) Pure red cell aplasia Destructive antibodies or lymphocytes \u2192 ineffective erythropoiesis Associated with thymoma, CLL and parvovirus infection, autoimmunity, drugs Diagnostic studies: lack of erythroid precursors on BM bx, other lines normal Treatment: thymectomy if thymus enlarged; IVIg if parvovirus and immunosuppressed (Clin Infect Dis 2013;56:968); immunosuppression/chemoRx if CLL or idiopathic; supportive care w/ PRBC transfusions; ? erythropoietin receptor agonist if due to antierythropoietin Ab (NEJM 2009;361:1848) consider hematopoietic cell transplantation. MACROCYTIC ANEMIAS includes megaloblastic and nonmegaloblastic causes Megaloblastic anemia Impaired DNA synthesis \u2192 cytoplasm matures faster than nucleus \u2192 ineffective erythropoiesis and macrocytosis; due to folate or B 12 deficiency; also in MDS \u2714 folate and vitamin B12; \u2191 LDH & indirect bilirubin (due to ineffective erythropoiesis) Smear: neutrophil hypersegmentation, macro-ovalocytes, anisocytosis, poikilocytosis Folate deficiency Folate present in leafy green vegetables and fruit; total body stores sufficient for 2\u20133 mo \u2022 Etiologies: malnutrition (alcoholics, anorectics, elderly), \u2193 absorption (sprue), impaired metabolism (methotrexate, pyrimethamine, trimethoprim; NEJM 2015;373:1649), \u2191 requirement (chronic hemolytic anemia, pregnancy, malignancy, dialysis) \u2022 Diagnosis: \u2193 folate; \u2193 RBC folate, \u2191 homocyst. but nl methylmalonic acid (unlike B 12 defic.) \u2022 Treatment: folate 1\u20135 mg PO qd for 1\u20134 mo or until complete hematologic recovery; critical to r/o B 12 deficiency first (see below) Vitamin B 12 deficiency (NEJM 2013;368:149) \u2022 B 12 present only in foods of animal origin; total body stores sufficient for 2\u20133 y \u2022 Binds to intrinsic factor (IF) secreted by gastric parietal cells; absorbed in terminal ileum \u2022 Etiologies: malnutrition (alcoholics, vegans), pernicious anemia (PA, autoimmune disease against gastric parietal cells, a/w polyglandular endocrine insufficiency and \u2191 risk of gastric carcinoma), other causes of \u2193 absorption (gastrectomy, sprue, Crohn\u2019s disease), \u2191 competition (intestinal bacterial overgrowth, fish tapeworm) \u2022 Clinical manifestations: neurologic changes (subacute combined degeneration) affecting peripheral nerves, posterior and lateral columns of the spinal cord and cortex \u2192 numbness, paresthesias, \u2193 vibratory and positional sense, ataxia, dementia \u2022 Dx: \u2193 B 12 ; \u2191 homocysteine and methylmalonic acid; anti-IF Ab; Schilling test; \u2191 gastrin in PA \u2022 Treatment: 1 mg B 12 IM qd \u00d7 7 d \u2192 q wk \u00d7 4\u20138 wk \u2192 q month for life neurologic abnormalities are reversible if treated w/in 6 mo folate can reverse hematologic abnormalities of B 12 deficiency but not neurologic changes (and can lead to \u201csteal\u201d of B 12 stores \u2192 worsening of neuro complications) oral supplementation (2 mg qd) appears feasible as well (Cochrane Rev CD004655) even w/o IF Nonmegaloblastic macrocytic anemias \u2022 Liver disease: often macrocytic, may see target cells, or spur cell anemia w/ hemolysis \u2022 Alcoholism: BM suppression & macrocytosis independent of folate/B 12 defic. or cirrhosis \u2022 Reticulocytosis \u2022 Other causes: hypothyroidism; MDS; meds that impair DNA synthesis (zidovudine, 5-FU, hydroxyurea, Ara-C); hereditary orotic aciduria; Lesch-Nyhan syndrome PANCYTOPENIA Etiologies \u2022 Hypocellular bone marrow (nl cellularity ~100 \u2013 age): aplastic anemia, hypoplastic MDS \u2022 Cellular bone marrow: MDS, aleukemic leukemia, PNH, severe megaloblastic anemia \u2022 Marrow replacement (myelophthisis): myelofibrosis, metastatic solid tumors, granulomas \u2022 Systemic diseases: hypersplenism, sepsis, alcohol, toxins Clinical manifestations \u2022 Anemia \u2192 fatigue \u2022 Neutropenia \u2192 recurrent infections \u2022 Thrombocytopenia \u2192 mucosal bleeding & easy bruisability Aplastic anemia = stem cell failure (NEJM 2015;373:35) \u2022 Epidemiology: 2\u20135 cases/10 6 /y; biphasic (major peak in adolescents, 2 nd peak in elderly) \u2022 Diagnosis: pancytopenia w/ \u2193 retics, BM bx w/ cytogenetics showing hypocellularity \u2022 Etiologies: idiopathic ( 1 / 2 \u2013 2 / 3 of cases) Stem cell destruction: radiation, chemotherapy, chemicals (eg, benzene) Idiosyncratic med rxn (eg, chloramphenicol, NSAIDs, sulfa drugs, gold, carbamazepine, antithyroid) Viruses (HHV-6, HIV, EBV, parvovirus B19); post-viral hepatic failure (not Hep A/B/C) Immune disorders (SLE, GVHD post-HSCT, thymoma) PNH (see below); Fanconi\u2019s anemia (congenital disorder w/ pancytopenia, macrocytic anemia, \u2191 risk of MDS, AML, & SCC of head & neck, and multiple physical anomalies) Shortened telomeres: seen w/ telomerase (TERT, TERC) mut. (10% of aplastic anemia), dyskeratosis congenita/DKC1 mut; a/w IPF, cirrhosis (NEJM 2009;361:2353) Somatic mutations: PNH clones in ~50% of aplastic anemia (Haematologica 2010;95:1075) \u2022 Treatment and prognosis Allogeneic HSCT: for young Pts \u2192 ~80% long-term survival and significantly \u2193 risk of malignant evolution, but has risk of transplant-related morbidity & mortality; if possible, avoid transfusions (and alloimmunization) pretransplant Immunosuppression (CsA/tacrolimus, ATG): 70\u201380% respond, with 80\u201390% 5-y survival in responders (96% vs. 76% w/ horse vs. rabbit ATG; NEJM 2011;365:430); 1520% 10-y incidence of clonal disorders (mostly MDS, AML, PNH) TPO mimetics (eg, eltrombopag) use 1 st -line w/ immunosuppression (NEJM 2017;376:1540) Supportive care: transfusions, abx, possible utility of G-CSF & Epo (if Epo <500) Myelodysplastic syndromes (MDS) (qv) Paroxysmal nocturnal hemoglobinuria (PNH) (Blood 2009;113:6522) \u2022 Acquired clonal stem cell disorder = inactivating somatic mutation of PIG-A gene \u2192 deficiency of GPI-anchor for CD55 & CD59 (inhib of complement) \u2192 complement-mediated RBC lysis, plt aggreg., & hypercoagulability \u2022 Clinical: intravascular hemolytic anemia, hypercoagulability (venous > arterial; esp. intraabdominal, cerebral), smooth muscle dystonias, deficient hematopoiesis (cytopenias); a/w aplastic anemia, MDS and evolution to AML \u2022 Dx: flow cytometry (\u2193 CD55 & CD59) on RBCs and granulocytes; urine hemosiderosis \u2022 Treatment: supportive care (iron, folate, transfusions); consider anticoagulation allogeneic HSCT for hypoplasia or severe thrombosis eculizumab (Ab inactivates terminal complement C5s): \u2193 hemolysis, improves QoL & stabilizes Hb levels (NEJM 2004;350:552 & 2006;355:1233; Lancet 2009;373:759); effective in pregnancy (NEJM 2015;373:1032); must have meningococcal vaccination Myelophthisic anemia (see also \u201cPrimary Myelofibrosis\u201d) \u2022 Infiltration of bone marrow by cancer, leukemia, infection, fibrosis (primary myelofi- brosis), granulomas, lysosomal storage disorders HEMOLYTIC ANEMIAS Diagnostic evaluation \u2022 \u2191 reticulocyte count (RI >2%), \u2191 LDH, \u2193 haptoglobin (83% Se, 96% Sp), \u2191 indirect bili \u2022 Autoimmune hemolysis: Coombs\u2019 test = direct antiglobulin test (DAT) \u2192 \u0370 if agglutination occurs when antisera against Ig or C3 are applied to patient RBCs \u2022 Intravascular: \u2191\u2191 LDH, \u2193\u2193 haptoglobin; hemoglobinemia, hemoglobinuria, hemosiderinuria \u2022 Extravascular: splenomegaly \u2022 Family h/o anemia; personal or family h/o cholelithiasis Glucose-6-phosphate dehydrogenase (G6PD) deficiency (Lancet 2008;371:64) X-linked defect of metabolism (G6PD mutations) w/ \u2191 susceptibility to \u2022 oxidative damage \u2022 Most common in \u2642 of African or Mediterranean descent (malariaendemic areas) \u2022 Hemolysis precipitated by drugs (sulfonamides, dapsone, nitrofurantoin, rasburicase, primaquine, doxorubicin, methylene blue), infxn, DKA, foods (favism, NEJM 2018;378:60) \u2022 Diagnosis: smear may show RBC Heinz bodies (oxidized Hb) that result in bite cells once removed by spleen; \u2193 G6PD levels (may be normal after acute hemolysis because older RBCs have already lysed and young RBCs may still have near-normal levels) Sickle cell anemia (NEJM 2017;376:1561 & Lancet 2017;390:311) \u2022 Recessive \u03b2-globin mutation \u2192 structurally abnl hemoglobin (HbS). ~8% African Americans heterozygotes (\u201csickle trait\u201d; usually w/o sx); ~1/400 homozygotes (sickle cell disease). \u2022 \u2193 O 2 \u2192 HbS polymerizes \u2192 RBC sickles, \u2193 RBC deformability \u2192 hemolysis & microvascular occlusion due to endothelial activ. & PMN adhesion (Blood 2013;122:3892) \u2022 Anemia: chronic hemolysis \u00b1 acute aplastic (parvo. B19) or splenic sequestration crises \u2022 Vaso-occlusion & infarction: acute chest syndrome & stroke (high mortality), pulmonary HTN, painful crises, splenic sequestration, renal papillary necrosis, aseptic necrosis, dactylitis (hand-foot syndrome), priapism \u2022 Infection: splenic infarction \u2192 overwhelming infection by encapsulated organisms; infarcted bone \u2192 osteomyelitis (Salmonella, Staph. aureus), can be life threatening \u2022 Diagnosis: sickle-shaped RBCs and Howell-Jolly bodies on smear; Hb electrophoresis \u2022 Treatment: hydroxyurea, folic acid; ? L-glutamine to prevent pain crises (NEJM 2018;379:226) \u2022 Vaccines: pneumo, meningo, H flu, HBV \u2022 Voxelotor (Hbs polymerization inhib) \u2191 hemolysis to \u2191 Hb (NEJM 2019;epub) \u2022 Pain & vaso-occlusive crises: analgesia (consider PCA), IVF, transfusion if sx & Hgb < baseline; crizanlizumab (anti-Pselectin; NEJM 2017;376:429) \u2022 Acute chest: O 2 , abx, IVF, exchange transfusion \u2022 TIA/stroke: often exchange transfusion (goal Hgb 10) \u00b1 thrombolytics \u2022 Gene therapy in development (NEJM 2017;376:848) Hereditary spherocytosis (HS) (Lancet 2008;372:1411) \u2022 Defect in a cytoskeletal protein of RBC membrane \u2192 membrane loss mutations in ankyrin, \u03b1- and \u03b2-spectrin, band 3, and pallidin have been identified \u2022 Most common in N. European populations (1/5000 births); \u0370 FHx (75% of Pts) \u2022 Anemia, jaundice (mostly neonates), splenomegaly, pigmented gallstones \u2022 Diagnosis: spherocytes on smear, \u0370 osmotic fragility test (~80% Se), \u2193 eosin-5-maleimide (EMA) binding (93% Se; 99% Sp; Haemat 2012;97:516), acidified glycerol lysis test (Se 95%) \u2022 Treatment: folate, transfusions, splenectomy for moderate and severe HS (balance w/ \u2191 risk of future thrombosis and infection; J Thromb Haemost 2008;6:1289) Paroxysmal nocturnal hemoglobinuria (see above) Autoimmune hemolytic anemia (AIHA) \u2022 Acquired, antibody-mediated RBC destruction \u2022 Warm AIHA: IgG Abs opsonize RBCs at body temp \u2192 removal by spleen Etiologies: idiopathic, lymphoproliferative (CLL, NHL), autoimmune (SLE), drugs, HIV, Babesiosis (NEJM 2017;376:939) \u2022 Cold AIHA: IgM Ab binds to RBCs at temp <37\u00b0C \u2192 complement fixation \u2192 intravascular hemolysis and acrocyanosis on exposure to cold Etiologies: idiopathic, lymphoprolif. disorders (eg, Waldenstr\u00f6m\u2019s; monoclonal), Mycoplasma pneumoniae infxn and infectious mononucleosis (polyclonal) \u2022 Diagnosis: spherocytes on smear, \u0370 Coombs\u2019; \u4ff6 cold agglutinin titer, splenomegaly \u2022 Treatment (Blood 2017;129:2971): treat underlying disease Warm AIHA: corticosteroids \u00b1 splenectomy, IVIg, cytotoxic agents, rituximab Cold AIHA: avoid cold; steroids ineffective; rituximab (Blood 2004;103:2925) Drug-induced hemolytic anemia \u2022 Acquired, Ab-mediated, RBC destruction precipitated by a med. Abx: ceph., sulfa drugs, rifampin, ribavirin. CV: methyldopa, procainamide, quinidine, thiazides. TCAs, phenothiazines, NSAIDs, sulfonylureas, MTX, 5-FU, rasburicase (G6PD defic.) \u2022 Diagnosis: Coombs\u2019 usually negative, \u2191 LDH; Treatment: discontinue offending agent Microangiopathic hemolytic anemia (MAHA; NEJM 2014;371:654) \u2022 Intra-arteriolar fibrin damages RBCs \u2192 acquired intravascular hemolysis \u2022 Etiologies: hemolytic-uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), disseminated intravascular coagulation (DIC), malignancy, malignant HTN, eclampsia/HELLP, mech. cardiac valves, infected vascular prostheses \u2022 Diagnosis: schistocytes \u00b1 thrombocytopenia \u00b1 abnormalities a/w specific disorders (eg, \u2191 PT in DIC, \u2191 Cr in HUS, \u2191 LFTs in HELLP) \u2022 Rx underlying dx; urgent plasma exchange w/ TTP (replace low ADAMTS13) Hypersplenism \u2022 Stasis/trapping in spleen \u2192 M\u03c6 attack & remodeling of RBC \u2192 spherocytosis \u2192 hemolysis Causes of Splenomegaly Etiology Comments* RES hyperplasia Hemolytic anemia, sickle cell disease, thalassemia major Immune hyperplasia Infxn [HIV, EBV, CMV, TB, malaria, kala azar (\u201cblack water fever\u201d from visceral leishmaniasis), Mycobacterium avium complex], autoimmune disorders (SLE, RA w/ Felty\u2019s syndrome), sarcoidosis, serum sickness Congestion Cirrhosis, CHF, portal/splenic vein thrombosis, schistosomiasis Infiltration (nonmalignant) Lysosomal storage disorders (Gaucher\u2019s, Niemann- Pick), glycogen storage diseases, histiocytosis X, splenic cysts Neoplasm MPN (CML, PMF, PV, ET), CMML, leukemia, lymphoma (NHL, HL, hairy cell leukemia, CLL, PLL, WM), T-LGL, myeloma, amyloid RES = reticuloendothelial system; *boldface = causes of massive splenomegaly.","title":"Anemia"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#anemia","text":"\u2193 in RBC mass: Hct <41% or Hb <13.5 g/dL (men); Hct <36% or Hb <12 g/dL (women)","title":"Anemia"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#clinical-manifestations","text":"Symptoms: \u2193 O 2 delivery \u2192 fatigue, exertional dyspnea, angina (if CAD) Signs: pallor (mucous membranes, palmar creases), tachycardia, orthostatic hypotension Other findings: jaundice (hemolysis), splenomegaly (thalassemia, neoplasm, chronic hemolysis), petechiae/purpura (bleeding disorder), glossitis (iron, folate, vitamin B 12 defic.), koilonychia (iron defic.), neurologic abnormalities (B 12 defic.)","title":"Clinical manifestations"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#diagnostic-evaluation","text":"History: bleeding, systemic illness, drugs, exposures, alcohol, diet (including pica), FHx CBC w/ diff.; RBC params incl. retics, MCV (nb, mixed disorder can \u2192 nl MCV), RDW Reticulocyte index (RI) = [reticulocyte count \u00d7 (Pt\u2019s Hct/nl Hct)]/maturation factor maturation factors for a given Hct: 45% = 1, 35% = 1.5, 25% = 2, 20% = 2.5 RI >2% \u2192 adequate marrow response; RI <2% \u2192 hypoproliferation Peripheral smear: select area where roughly \u2153 RBCs touch each other; \u4ff6 RBC size, shape, inclusions (see \u201cAppendix\u201d & \u201cPeripheral Smear\u201d), WBC morphology, plt count Additional labs as indicated: hemolysis labs (if RI >2%, see below), iron/TIBC, ferritin, folate, B 12 , LFTs, BUN & Cr, TFTs, Hb electrophoresis, enzyme/gene mutation screens \u2022 Bone marrow (BM) aspirate and biopsy (bx) with cytogenetics as indicated Figure 5-1 Approach to anemia and common causes","title":"Diagnostic evaluation"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#microcytic-anemias","text":"Figure 5-2 Approach to microcytic anemias (NEJM 2014;371:1324)","title":"MICROCYTIC ANEMIAS"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#iron-deficiency-nejm-20153721832-lancet-2016387907","text":"\u2193 marrow iron & depleted body iron stores \u2192 \u2193 heme synthesis \u2192 microcytosis \u2192 anemia Special clinical manifestations: angular cheilosis, atrophic glossitis, pica (consumption of nonnutritive substances such as ice, clay), koilonychia (nail spooning) Plummer-Vinson syndrome (iron deficiency anemia, esophageal web & atrophic glossitis) Etiologies: chronic bleeding (GI\u2014incl. cancer, menstrual, parasites, NSAIDs, etc.), \u2193 supply (malnutrition; \u2193 absorp. due to celiac sprue, Crohn\u2019s, \u2191 gastric pH, subtotal gastrectomy), \u2191 demand (preg; Blood 2017;129:940). Iron-refractory iron-defic. anemia (IRIDA; rare genetic disorder due to hepcidin dysregulation; Nat Genet 2008;40:569). Diagnosis (eval ideally before Rx): \u2193 Fe, \u2191 TIBC, \u2193 ferritin (esp. <15), \u2193 transferrin sat (Fe/TIBC; esp. <15%), \u2191 soluble transferrin receptor; \u2191 plt. Unless hx c/w other etiology, initiate workup for GIB, incl. H. pylori serology. ? Celiac labs (antiTTG, antigliadin, anti-endomysial Abs). Cytogenetics & molecular testing as indicated. Treatment: oral Fe tid (~6 wks to correct anemia; ~6 mo to replete Fe stores; nb, oral Fe does not give \u0370 Hemoccult). In excessive/persistent GI losses or dialysis, cancer, CHF, or prior to Epo Rx, IV iron (Fe-sucrose, -gluconate, -dextran) should be considered.","title":"Iron deficiency (NEJM 2015;372:1832; Lancet 2016;387:907)"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#thalassemias-lancet-2018391155","text":"\u2193 synthesis of \u03b1- or \u03b2-globin chains of Hb \u2192 \u2260 subunits \u2192 destruction of RBCs and erythroid precursors; \u0127 anemia from hemolysis and ineffective erythropoiesis \u03b1-thalassemia (NEJM 2014;371:1908): deletions in \u03b1-globin gene complex (nl 4 \u03b1 genes), seen w/ Southeast Asian, Mediterranean, African, Middle East ancestry 3 \u03b1 \u2192 \u03b1-thal-2 trait = silent carrier; 2 \u03b1 \u2192 \u03b1-thal-1 trait or \u03b1thal minor = mild anemia 1 \u03b1 \u2192 HbH (\u03b2 4 ) disease = severe anemia, hemolysis, and splenomegaly 0 \u03b1 genes \u2192 Hb Barts (\u03b3 4 ) = intrauterine hypoxia and hydrops fetalis \u03b2-thalassemia: mutations in \u03b2-globin gene \u2192 absent or \u2193 gene product seen w/ Mediterranean (espec. Greek or Italian), African, or Asian ancestry 1 mutated \u03b2 gene \u2192 thal minor (or trait) = mild anemia (no transfusions) 2 mutated \u03b2 genes \u2192 thal intermedia (occasional transfusions) or thal major (= Cooley\u2019s anemia; transfusion dependent) depending on severity of mutations Special clinical manifestations: chipmunk facies, pathologic fractures, hepatosplenomegaly (due to extramedullary hematopoiesis), high-output CHF, bilirubin gallstones, Fe overload Dx: MCV <70, normal Fe, ferritin, MCV/RBC count <13 [Mentzer Index, 60% Se, 98% Sp; (Ann Hem 2007;86:486)], \u00b1 \u2191 retics, basophilic stippling; Hb electrophoresis: \u2191 HbA 2 (\u03b1 2 \u03b4 2 ) in \u03b2-thal; normal pattern in \u03b1-thal trait, \u0127 PCR or supravital stain for dx Treatment: folate; transfusions + Fe chelator [either deferoxamine (IV) or deferasirox (PO)]; ? splenectomy if \u226550% \u2191 in transfusions; consider allo-HSCT in children w/ severe \u03b2thal; gene therapy in development (NEJM 2018;378:1479)","title":"Thalassemias (Lancet 2018;391:155)"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#anemia-of-chronic-inflammation-see-below","text":"","title":"Anemia of chronic inflammation (see below)"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#sideroblastic-anemia","text":"Defective heme biosynthesis within RBC precursors Etiologies: hereditary/X-linked (ALAS2 mutations), idiopathic, MDS-RARS, reversible (alcohol, lead, isoniazid, chloramphenicol, copper deficiency, hypothermia) Special clinical manifestations: hepatosplenomegaly, iron overload syndromes Dx: social, work & TB hx; can be micro-, normo-, or macrocytic; variable populations of hypochromic RBCs; \u2191 Fe, nl TIBC, \u2191 ferritin, basophilic stippling, RBC Pappenheimer bodies (Fecontaining inclusions), ring sideroblasts (w/ iron-laden mitochondria) in BM Treatment: treat reversible causes; trial of pyridoxine, supportive transfusions for severe anemia with chelation therapy; highdose pyridoxine for some hereditary cases","title":"Sideroblastic anemia"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#normocytic-anemias","text":"","title":"NORMOCYTIC ANEMIAS"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#pancytopenia-see-below","text":"","title":"Pancytopenia (see below)"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#anemia-of-chronic-inflammation-aci-nejm-20123664","text":"\u2193 RBC production due to impaired iron utilization and functional iron deficiency from \u2191 hepcidin; cytokines (IL-6, TNF-\u03b1) cause \u2193 Epo responsiveness/production Etiologies: autoimmune disorders, chronic infection, inflammation, HIV, malignancy Dx: \u2193 Fe, \u2193 TIBC (usually normal or low transferrin sat), \u00b1 \u2191 ferritin; usually normochromic, normocytic (~70% of cases) but can be microcytic if prolonged Coexisting iron deficiency common. Dx clues include \u2193 serum ferritin levels, absence of iron staining on BM bx, \u0370 response to a trial of oral iron and/or \u2191 soluble transferrin receptor/ferritin index (Am J Clin Pathol 2012;138:642). Treatment: treat underlying disease \u00b1 iron and/or erythropoiesisstimulating agent (ESA; eg, Epo). Iron if ferritin <100 or Fe/TIBC <20%. Consider ESA if Epo <500. Avoid ESA in cancer if treatment goal is cure (Lancet 2009;373:1532). Transfuse PRBCs only if symptomatic & insufficient time to wait for response to Epo or underlying disease Rx.","title":"Anemia of chronic inflammation (ACI; NEJM 2012;366:4)"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#anemias-of-other-chronic-disorders","text":"Anemia of chronic kidney disease: \u2193 Epo; treat w/ Epo (see \u201cChronic Kidney Disease\u201d) Endocrine deficiencies: hypometabolism and \u2193 O 2 demand with thyroid, pituitary, adrenal, or parathyroid disease \u2192 \u2193 Epo; can be normocytic or macrocytic","title":"Anemias of other chronic disorders"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#sideroblastic-anemia-see-above","text":"","title":"Sideroblastic anemia (see above)"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#pure-red-cell-aplasia","text":"Destructive antibodies or lymphocytes \u2192 ineffective erythropoiesis Associated with thymoma, CLL and parvovirus infection, autoimmunity, drugs Diagnostic studies: lack of erythroid precursors on BM bx, other lines normal Treatment: thymectomy if thymus enlarged; IVIg if parvovirus and immunosuppressed (Clin Infect Dis 2013;56:968); immunosuppression/chemoRx if CLL or idiopathic; supportive care w/ PRBC transfusions; ? erythropoietin receptor agonist if due to antierythropoietin Ab (NEJM 2009;361:1848) consider hematopoietic cell transplantation.","title":"Pure red cell aplasia"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#macrocytic-anemias","text":"includes megaloblastic and nonmegaloblastic causes","title":"MACROCYTIC ANEMIAS"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#megaloblastic-anemia","text":"Impaired DNA synthesis \u2192 cytoplasm matures faster than nucleus \u2192 ineffective erythropoiesis and macrocytosis; due to folate or B 12 deficiency; also in MDS \u2714 folate and vitamin B12; \u2191 LDH & indirect bilirubin (due to ineffective erythropoiesis) Smear: neutrophil hypersegmentation, macro-ovalocytes, anisocytosis, poikilocytosis","title":"Megaloblastic anemia"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#folate-deficiency","text":"Folate present in leafy green vegetables and fruit; total body stores sufficient for 2\u20133 mo \u2022 Etiologies: malnutrition (alcoholics, anorectics, elderly), \u2193 absorption (sprue), impaired metabolism (methotrexate, pyrimethamine, trimethoprim; NEJM 2015;373:1649), \u2191 requirement (chronic hemolytic anemia, pregnancy, malignancy, dialysis) \u2022 Diagnosis: \u2193 folate; \u2193 RBC folate, \u2191 homocyst. but nl methylmalonic acid (unlike B 12 defic.) \u2022 Treatment: folate 1\u20135 mg PO qd for 1\u20134 mo or until complete hematologic recovery; critical to r/o B 12 deficiency first (see below) Vitamin B 12 deficiency (NEJM 2013;368:149) \u2022 B 12 present only in foods of animal origin; total body stores sufficient for 2\u20133 y \u2022 Binds to intrinsic factor (IF) secreted by gastric parietal cells; absorbed in terminal ileum \u2022 Etiologies: malnutrition (alcoholics, vegans), pernicious anemia (PA, autoimmune disease against gastric parietal cells, a/w polyglandular endocrine insufficiency and \u2191 risk of gastric carcinoma), other causes of \u2193 absorption (gastrectomy, sprue, Crohn\u2019s disease), \u2191 competition (intestinal bacterial overgrowth, fish tapeworm) \u2022 Clinical manifestations: neurologic changes (subacute combined degeneration) affecting peripheral nerves, posterior and lateral columns of the spinal cord and cortex \u2192 numbness, paresthesias, \u2193 vibratory and positional sense, ataxia, dementia \u2022 Dx: \u2193 B 12 ; \u2191 homocysteine and methylmalonic acid; anti-IF Ab; Schilling test; \u2191 gastrin in PA \u2022 Treatment: 1 mg B 12 IM qd \u00d7 7 d \u2192 q wk \u00d7 4\u20138 wk \u2192 q month for life neurologic abnormalities are reversible if treated w/in 6 mo folate can reverse hematologic abnormalities of B 12 deficiency but not neurologic changes (and can lead to \u201csteal\u201d of B 12 stores \u2192 worsening of neuro complications) oral supplementation (2 mg qd) appears feasible as well (Cochrane Rev CD004655) even w/o IF Nonmegaloblastic macrocytic anemias \u2022 Liver disease: often macrocytic, may see target cells, or spur cell anemia w/ hemolysis \u2022 Alcoholism: BM suppression & macrocytosis independent of folate/B 12 defic. or cirrhosis \u2022 Reticulocytosis \u2022 Other causes: hypothyroidism; MDS; meds that impair DNA synthesis (zidovudine, 5-FU, hydroxyurea, Ara-C); hereditary orotic aciduria; Lesch-Nyhan syndrome","title":"Folate deficiency"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#pancytopenia","text":"Etiologies \u2022 Hypocellular bone marrow (nl cellularity ~100 \u2013 age): aplastic anemia, hypoplastic MDS \u2022 Cellular bone marrow: MDS, aleukemic leukemia, PNH, severe megaloblastic anemia \u2022 Marrow replacement (myelophthisis): myelofibrosis, metastatic solid tumors, granulomas \u2022 Systemic diseases: hypersplenism, sepsis, alcohol, toxins Clinical manifestations \u2022 Anemia \u2192 fatigue \u2022 Neutropenia \u2192 recurrent infections \u2022 Thrombocytopenia \u2192 mucosal bleeding & easy bruisability Aplastic anemia = stem cell failure (NEJM 2015;373:35) \u2022 Epidemiology: 2\u20135 cases/10 6 /y; biphasic (major peak in adolescents, 2 nd peak in elderly) \u2022 Diagnosis: pancytopenia w/ \u2193 retics, BM bx w/ cytogenetics showing hypocellularity \u2022 Etiologies: idiopathic ( 1 / 2 \u2013 2 / 3 of cases) Stem cell destruction: radiation, chemotherapy, chemicals (eg, benzene) Idiosyncratic med rxn (eg, chloramphenicol, NSAIDs, sulfa drugs, gold, carbamazepine, antithyroid) Viruses (HHV-6, HIV, EBV, parvovirus B19); post-viral hepatic failure (not Hep A/B/C) Immune disorders (SLE, GVHD post-HSCT, thymoma) PNH (see below); Fanconi\u2019s anemia (congenital disorder w/ pancytopenia, macrocytic anemia, \u2191 risk of MDS, AML, & SCC of head & neck, and multiple physical anomalies) Shortened telomeres: seen w/ telomerase (TERT, TERC) mut. (10% of aplastic anemia), dyskeratosis congenita/DKC1 mut; a/w IPF, cirrhosis (NEJM 2009;361:2353) Somatic mutations: PNH clones in ~50% of aplastic anemia (Haematologica 2010;95:1075) \u2022 Treatment and prognosis Allogeneic HSCT: for young Pts \u2192 ~80% long-term survival and significantly \u2193 risk of malignant evolution, but has risk of transplant-related morbidity & mortality; if possible, avoid transfusions (and alloimmunization) pretransplant Immunosuppression (CsA/tacrolimus, ATG): 70\u201380% respond, with 80\u201390% 5-y survival in responders (96% vs. 76% w/ horse vs. rabbit ATG; NEJM 2011;365:430); 1520% 10-y incidence of clonal disorders (mostly MDS, AML, PNH) TPO mimetics (eg, eltrombopag) use 1 st -line w/ immunosuppression (NEJM 2017;376:1540) Supportive care: transfusions, abx, possible utility of G-CSF & Epo (if Epo <500) Myelodysplastic syndromes (MDS) (qv) Paroxysmal nocturnal hemoglobinuria (PNH) (Blood 2009;113:6522) \u2022 Acquired clonal stem cell disorder = inactivating somatic mutation of PIG-A gene \u2192 deficiency of GPI-anchor for CD55 & CD59 (inhib of complement) \u2192 complement-mediated RBC lysis, plt aggreg., & hypercoagulability \u2022 Clinical: intravascular hemolytic anemia, hypercoagulability (venous > arterial; esp. intraabdominal, cerebral), smooth muscle dystonias, deficient hematopoiesis (cytopenias); a/w aplastic anemia, MDS and evolution to AML \u2022 Dx: flow cytometry (\u2193 CD55 & CD59) on RBCs and granulocytes; urine hemosiderosis \u2022 Treatment: supportive care (iron, folate, transfusions); consider anticoagulation allogeneic HSCT for hypoplasia or severe thrombosis eculizumab (Ab inactivates terminal complement C5s): \u2193 hemolysis, improves QoL & stabilizes Hb levels (NEJM 2004;350:552 & 2006;355:1233; Lancet 2009;373:759); effective in pregnancy (NEJM 2015;373:1032); must have meningococcal vaccination Myelophthisic anemia (see also \u201cPrimary Myelofibrosis\u201d) \u2022 Infiltration of bone marrow by cancer, leukemia, infection, fibrosis (primary myelofi- brosis), granulomas, lysosomal storage disorders","title":"PANCYTOPENIA"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#hemolytic-anemias","text":"Diagnostic evaluation \u2022 \u2191 reticulocyte count (RI >2%), \u2191 LDH, \u2193 haptoglobin (83% Se, 96% Sp), \u2191 indirect bili \u2022 Autoimmune hemolysis: Coombs\u2019 test = direct antiglobulin test (DAT) \u2192 \u0370 if agglutination occurs when antisera against Ig or C3 are applied to patient RBCs \u2022 Intravascular: \u2191\u2191 LDH, \u2193\u2193 haptoglobin; hemoglobinemia, hemoglobinuria, hemosiderinuria \u2022 Extravascular: splenomegaly \u2022 Family h/o anemia; personal or family h/o cholelithiasis Glucose-6-phosphate dehydrogenase (G6PD) deficiency (Lancet 2008;371:64) X-linked defect of metabolism (G6PD mutations) w/ \u2191 susceptibility to \u2022 oxidative damage \u2022 Most common in \u2642 of African or Mediterranean descent (malariaendemic areas) \u2022 Hemolysis precipitated by drugs (sulfonamides, dapsone, nitrofurantoin, rasburicase, primaquine, doxorubicin, methylene blue), infxn, DKA, foods (favism, NEJM 2018;378:60) \u2022 Diagnosis: smear may show RBC Heinz bodies (oxidized Hb) that result in bite cells once removed by spleen; \u2193 G6PD levels (may be normal after acute hemolysis because older RBCs have already lysed and young RBCs may still have near-normal levels) Sickle cell anemia (NEJM 2017;376:1561 & Lancet 2017;390:311) \u2022 Recessive \u03b2-globin mutation \u2192 structurally abnl hemoglobin (HbS). ~8% African Americans heterozygotes (\u201csickle trait\u201d; usually w/o sx); ~1/400 homozygotes (sickle cell disease). \u2022 \u2193 O 2 \u2192 HbS polymerizes \u2192 RBC sickles, \u2193 RBC deformability \u2192 hemolysis & microvascular occlusion due to endothelial activ. & PMN adhesion (Blood 2013;122:3892) \u2022 Anemia: chronic hemolysis \u00b1 acute aplastic (parvo. B19) or splenic sequestration crises \u2022 Vaso-occlusion & infarction: acute chest syndrome & stroke (high mortality), pulmonary HTN, painful crises, splenic sequestration, renal papillary necrosis, aseptic necrosis, dactylitis (hand-foot syndrome), priapism \u2022 Infection: splenic infarction \u2192 overwhelming infection by encapsulated organisms; infarcted bone \u2192 osteomyelitis (Salmonella, Staph. aureus), can be life threatening \u2022 Diagnosis: sickle-shaped RBCs and Howell-Jolly bodies on smear; Hb electrophoresis \u2022 Treatment: hydroxyurea, folic acid; ? L-glutamine to prevent pain crises (NEJM 2018;379:226) \u2022 Vaccines: pneumo, meningo, H flu, HBV \u2022 Voxelotor (Hbs polymerization inhib) \u2191 hemolysis to \u2191 Hb (NEJM 2019;epub) \u2022 Pain & vaso-occlusive crises: analgesia (consider PCA), IVF, transfusion if sx & Hgb < baseline; crizanlizumab (anti-Pselectin; NEJM 2017;376:429) \u2022 Acute chest: O 2 , abx, IVF, exchange transfusion \u2022 TIA/stroke: often exchange transfusion (goal Hgb 10) \u00b1 thrombolytics \u2022 Gene therapy in development (NEJM 2017;376:848) Hereditary spherocytosis (HS) (Lancet 2008;372:1411) \u2022 Defect in a cytoskeletal protein of RBC membrane \u2192 membrane loss mutations in ankyrin, \u03b1- and \u03b2-spectrin, band 3, and pallidin have been identified \u2022 Most common in N. European populations (1/5000 births); \u0370 FHx (75% of Pts) \u2022 Anemia, jaundice (mostly neonates), splenomegaly, pigmented gallstones \u2022 Diagnosis: spherocytes on smear, \u0370 osmotic fragility test (~80% Se), \u2193 eosin-5-maleimide (EMA) binding (93% Se; 99% Sp; Haemat 2012;97:516), acidified glycerol lysis test (Se 95%) \u2022 Treatment: folate, transfusions, splenectomy for moderate and severe HS (balance w/ \u2191 risk of future thrombosis and infection; J Thromb Haemost 2008;6:1289) Paroxysmal nocturnal hemoglobinuria (see above) Autoimmune hemolytic anemia (AIHA) \u2022 Acquired, antibody-mediated RBC destruction \u2022 Warm AIHA: IgG Abs opsonize RBCs at body temp \u2192 removal by spleen Etiologies: idiopathic, lymphoproliferative (CLL, NHL), autoimmune (SLE), drugs, HIV, Babesiosis (NEJM 2017;376:939) \u2022 Cold AIHA: IgM Ab binds to RBCs at temp <37\u00b0C \u2192 complement fixation \u2192 intravascular hemolysis and acrocyanosis on exposure to cold Etiologies: idiopathic, lymphoprolif. disorders (eg, Waldenstr\u00f6m\u2019s; monoclonal), Mycoplasma pneumoniae infxn and infectious mononucleosis (polyclonal) \u2022 Diagnosis: spherocytes on smear, \u0370 Coombs\u2019; \u4ff6 cold agglutinin titer, splenomegaly \u2022 Treatment (Blood 2017;129:2971): treat underlying disease Warm AIHA: corticosteroids \u00b1 splenectomy, IVIg, cytotoxic agents, rituximab Cold AIHA: avoid cold; steroids ineffective; rituximab (Blood 2004;103:2925) Drug-induced hemolytic anemia \u2022 Acquired, Ab-mediated, RBC destruction precipitated by a med. Abx: ceph., sulfa drugs, rifampin, ribavirin. CV: methyldopa, procainamide, quinidine, thiazides. TCAs, phenothiazines, NSAIDs, sulfonylureas, MTX, 5-FU, rasburicase (G6PD defic.) \u2022 Diagnosis: Coombs\u2019 usually negative, \u2191 LDH; Treatment: discontinue offending agent Microangiopathic hemolytic anemia (MAHA; NEJM 2014;371:654) \u2022 Intra-arteriolar fibrin damages RBCs \u2192 acquired intravascular hemolysis \u2022 Etiologies: hemolytic-uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), disseminated intravascular coagulation (DIC), malignancy, malignant HTN, eclampsia/HELLP, mech. cardiac valves, infected vascular prostheses \u2022 Diagnosis: schistocytes \u00b1 thrombocytopenia \u00b1 abnormalities a/w specific disorders (eg, \u2191 PT in DIC, \u2191 Cr in HUS, \u2191 LFTs in HELLP) \u2022 Rx underlying dx; urgent plasma exchange w/ TTP (replace low ADAMTS13) Hypersplenism \u2022 Stasis/trapping in spleen \u2192 M\u03c6 attack & remodeling of RBC \u2192 spherocytosis \u2192 hemolysis","title":"HEMOLYTIC ANEMIAS"},{"location":"05-%E8%A1%80%E8%85%AB/05-01-Anemia/#causes-of-splenomegaly","text":"Etiology Comments* RES hyperplasia Hemolytic anemia, sickle cell disease, thalassemia major Immune hyperplasia Infxn [HIV, EBV, CMV, TB, malaria, kala azar (\u201cblack water fever\u201d from visceral leishmaniasis), Mycobacterium avium complex], autoimmune disorders (SLE, RA w/ Felty\u2019s syndrome), sarcoidosis, serum sickness Congestion Cirrhosis, CHF, portal/splenic vein thrombosis, schistosomiasis Infiltration (nonmalignant) Lysosomal storage disorders (Gaucher\u2019s, Niemann- Pick), glycogen storage diseases, histiocytosis X, splenic cysts Neoplasm MPN (CML, PMF, PV, ET), CMML, leukemia, lymphoma (NHL, HL, hairy cell leukemia, CLL, PLL, WM), T-LGL, myeloma, amyloid RES = reticuloendothelial system; *boldface = causes of massive splenomegaly.","title":"Causes of Splenomegaly"},{"location":"05-%E8%A1%80%E8%85%AB/05-02-Disorders-of-Hemostasis/","text":"","title":"05 02 Disorders of Hemostasis"},{"location":"05-%E8%A1%80%E8%85%AB/05-03-Platelet-Disorders/","text":"","title":"05 03 Platelet Disorders"},{"location":"05-%E8%A1%80%E8%85%AB/05-04-Coagulopathies/","text":"","title":"05 04 Coagulopathies"},{"location":"05-%E8%A1%80%E8%85%AB/05-05-Hypercoagulable-States/","text":"","title":"05 05 Hypercoagulable States"},{"location":"05-%E8%A1%80%E8%85%AB/05-06-Disorders-of-Leukocytes/","text":"","title":"05 06 Disorders of Leukocytes"},{"location":"05-%E8%A1%80%E8%85%AB/05-07-Transfusion-Therapy/","text":"","title":"05 07 Transfusion Therapy"},{"location":"05-%E8%A1%80%E8%85%AB/05-08-Myelodysplastic-Syndromes/","text":"","title":"05 08 Myelodysplastic Syndromes"},{"location":"05-%E8%A1%80%E8%85%AB/05-09-Myeloproliferative-Neoplasms/","text":"","title":"05 09 Myeloproliferative Neoplasms"},{"location":"05-%E8%A1%80%E8%85%AB/05-10-Leukemia-Lymphoma/","text":"","title":"05 10 Leukemia Lymphoma"},{"location":"05-%E8%A1%80%E8%85%AB/05-11-Plasma-Cell-Dyscrasias/","text":"","title":"05 11 Plasma Cell Dyscrasias"},{"location":"05-%E8%A1%80%E8%85%AB/05-12-Hematopoietic-Stem-Cell-Transplantation/","text":"","title":"05 12 Hematopoietic Stem Cell Transplantation"},{"location":"05-%E8%A1%80%E8%85%AB/05-13-Lung-Cancer/","text":"","title":"05 13 Lung Cancer"},{"location":"05-%E8%A1%80%E8%85%AB/05-14-Breast-Cancer/","text":"","title":"05 14 Breast Cancer"},{"location":"05-%E8%A1%80%E8%85%AB/05-15-Prostate-Cancer/","text":"","title":"05 15 Prostate Cancer"},{"location":"05-%E8%A1%80%E8%85%AB/05-16-Colorectal-Cancer/","text":"","title":"05 16 Colorectal Cancer"},{"location":"05-%E8%A1%80%E8%85%AB/05-17-Pancreatic-Tumors/","text":"","title":"05 17 Pancreatic Tumors"},{"location":"05-%E8%A1%80%E8%85%AB/05-18-Hepatocellular-Carcinoma/","text":"","title":"05 18 Hepatocellular Carcinoma"},{"location":"05-%E8%A1%80%E8%85%AB/05-19-Oncologic-Emergencies/","text":"","title":"05 19 Oncologic Emergencies"},{"location":"05-%E8%A1%80%E8%85%AB/05-20-Chemotherapy-Side-Effects/","text":"","title":"05 20 Chemotherapy Side Effects"},{"location":"06-%E6%84%9F%E6%9F%93/06-01-Pneumonia/","text":"Pneumonia 2018\u53f0\u7063\u80ba\u708e\u6307\u5f15 Microbiology of Pneumonia Clinical Setting \u539f\u56e0 Community- acquired (CAP) ( NEJM 2014;371:1619 & 373:415; Lancet 2015;386:1097) No pathogen identified in 50\u201360%, virus alone in ~25%, bacteria alone in ~10%, virus-bacteria coinfection in <5% Viruses: influenza, RSV, hMPV, rhinovirus (unknown significance), parainfluenza virus, coronavirus S. pneumoniae (most common bacterial cause) S. aureus (esp. postinfluenza) Mycoplasma, Chlamydia (\u7279\u5225\u5728 young & healthy) H. influenzae, M. catarrhalis (\u7279\u5225\u5728 COPD) Legionella (\u7279\u5225\u5728 elderly, smokers, \u2193 immunity, TNF inhibitors) Klebsiella & other GNR (\u7279\u5225\u5728 alcoholics & aspiration) Hospital-acquired or ventilator-assoc. (HAP/VAP) S. aureus, Pseudo., Klebsiella, E. coli, Enterobacter, Acinetobacter, Stenotrophomonas. IV abx w/in 90 d RF for MDR. Viral~ 20% cases (Chest 2017; 154:1) Immunosuppressed Above + PCP, fungi, Nocardia, non-TB mycobacteria (NTM), CMV Aspiration (NEJM 2019;380:651) Chemical pneumonitis due to aspiration of gastric contents Bacterial pneumonia \u226524\u201372 h after aspiration event outPt: oral flora (strep, S. aureus, anaerobes) inPt or chronically ill: GNR (Pseudomonas) and S. aureus Clinical manifestations Presenting features are variable and depend upon several host factors (esp. age) Classically: fever, cough w/ purulent sputum, consolidation on CXR Atypical pathogens (Legionella, Mycoplasma, Chlamydia, virus): historically classified as \u201catypical\u201d b/c they failed to grow on routine cx. Presentation varies from insidious to acute; imaging features vary from interstitial infiltrates to tree-in-bud opacities, to dense consolid. Clinical and imaging features do NOT distinguish \u201ctypical\u201d from \u201catypical\u201d Aspiration pneumonitis/PNA: can be infectious or non-infectious; may p/w acute inflammatory syndrome (fever, \u2191 WBC, etc.) or insidious course HAP/VAP: develops w/in 48 h after admission or mechanical ventilation, respectively Diagnostic studies Sputum Gram stain/Cx: reliable if high quality (ie, sputum not spit; <10 squamous cells/lpf) & if PNA should be purulent (>25 PMNs/lpf). Yield \u2193 >10 h after abx (CID 2014;58:1782). Blood cultures (before antibiotics!): \u2295 in ~10% of inPts, depending on pathogen Procalcitonin: \u2191 in acute bacterial (not viral) PNA. Consider stopping abx if levels <0.25 ng/ml (<0.5 ng/ml in ICU Pts) or \u2193 \u226580% from peak. \u2193 abx exposure by 2\u20133 d (Lancet ID 2016;16:819 & 2018;18:95). Not validated in immunocompromised hosts. Levels harder to interpret in CKD. False \u2295 in cardiac arrest, shock, surgery. CXR (PA & lateral; see Radiology inserts) \u2192 tap effusions if >5 cm or severe PNA Other: S a O 2 or P a O 2 , arterial pH (if severe), CBC w/ diff, Chem-20; HIV test (if unknown) Other micro based on clinical suspicion (paired serologies available for most atypicals): Mycoplasma: PCR of throat or sputum/BAL before first dose abx Legionella urinary Ag (detects L. pneumophila L1 serotype, 60\u201370% of clinical disease) S. pneumoniae urinary Ag (Se 70%, Sp >90%) MTb: (induced) sputum AFB stain \u00d73 q \u22658h (w/ \u22651 early morning specimen). Myco-bacterial cx (empiric respiratory isolation while pending); MTb DNA PCR if smear \u2295 Viral testing (DFA or PCR) on nasopharyngeal swab or sputum Bronchoscopy: consider if immunosupp., critically ill, failing to respond, VAP, suspected TB or PCP, or inadequate or \u0398 sputum cx. Some pathogens need specific cx media (eg, Legionella on BCYE). Reasons for failure to improve on initial Rx: Insufficient time: may take \u226572 h to see improvement (fever persists >4 d in ~20%) Insufficient drug levels for lung penetration (eg, vanco trough <15\u201320 \u00b5g/mL) Resistant organisms (or superinfxn): eg, MRSA, Pseudo.; consider bronchoscopy Wrong dx: fungal/viral, chemical pneumonitis, PE, CHF, ARDS, DAH, ILD; consider CT Parapneumonic effusion/empyema/abscess: if CXR \u0398, consider CT (dx tap \u00b1 chest tube if effusion present, esp. if loculated) Metastatic infection (eg, endocarditis, meningitis, septic arthritis) Triage qSOFA predicts poor outcomes, prolonged ICU stay, and inhospital mortality if >2 of 3: RR>22, AMS, SBP<100 (JAMA 2016; 315:801) CURB-65: confusion, BUN >20, RR >30, BP <90/60, age >65 If score 0\u20131: Rx as outpt; 2: Rx as inpt; >3 consider ICU (Thorax 2013; 58:377) Treatment Scenario Regimen Special Considerations CAP (outPt) Azithro or doxy Avoid azithro/doxycycline if >25% resist- ance locally. Use FQ OR B-lactam + azithro/doxy. CAP (ward) Resp FQ or [3 rd -gen ceph + azithro] Doxycycline can replace azithro Omadacycline \u2248 FQ (NEJM 2019;380:517) CAP (ICU) Resp FQ + [3 rd -gen ceph or amp-sulbactam] Only cover MRSA or Pseudomonas if risk factors. If resp FQ contraindic., use azithro HCAP (incl. VAP) [Pip-tazo or cefepime or carbapen.] + [vanco or linezolid]395 May add resp FQ (or azithro) when concerned re: atypicals Aspiration Treat if abnl CXR (or if need to be intubated or develops septic shock) Amox-clav, amp-sulbactam, FQ, carbapenem If hosp-acquired and concern for multidrug-resistant pathogens: [pip-tazo, cefepime, or carbapenem] + [AG or colistin] Avoid quinolones if suspect TB Steroids: not standard practice, but appear to \u2193 mortality, mech vent, & ARDS (Cochrane 2017;12:CD007720). Consider in severe CAP (F i O 2 >0.5 + \u22651 of: pH<7.3; lactate >4; CRP >150). Avoid in suspected or known influenza. Dosing: pred 50 mg PO \u00d77 d or methylpred 0.5 mg/kg IV BID \u00d75 d. Duration: for CAP, 5 d if stable & afebrile for 48\u201372 h; for HAP/VAP, 8 d (CID 2017; 65:8) When possible, de-escalate abx based on sensitivities Prognosis For low-risk Pts, can discharge immediately after switching to PO abx (CID 2007;44:S27) CXR resolves in most by 6 wk; consider f/u to r/o underlying malig (esp. if >50 y or smoker) Prevention All persons >65: give PCV13 vaccine followed by PPSV23 vaccine 1 y later. If PPSV23 already received, give PCV13. Age 19\u201364 w/ CHF/CMP, lung disease (including asthma), cirrhosis, DM, EtOH, or smoker: give PPSV23 Any age w/ immunocomp., CSF leak, cochlear implant, asplenia: give PCV13 followed by PPSV23 8 wks later. Smoking cessation counseling VAP precautions: HOB >30\u00b0, chlorhexidine rinse; aspiration precautions in high-risk Pts","title":"Pneumonia"},{"location":"06-%E6%84%9F%E6%9F%93/06-01-Pneumonia/#pneumonia","text":"2018\u53f0\u7063\u80ba\u708e\u6307\u5f15","title":"Pneumonia"},{"location":"06-%E6%84%9F%E6%9F%93/06-01-Pneumonia/#microbiology-of-pneumonia","text":"Clinical Setting \u539f\u56e0 Community- acquired (CAP) ( NEJM 2014;371:1619 & 373:415; Lancet 2015;386:1097) No pathogen identified in 50\u201360%, virus alone in ~25%, bacteria alone in ~10%, virus-bacteria coinfection in <5% Viruses: influenza, RSV, hMPV, rhinovirus (unknown significance), parainfluenza virus, coronavirus S. pneumoniae (most common bacterial cause) S. aureus (esp. postinfluenza) Mycoplasma, Chlamydia (\u7279\u5225\u5728 young & healthy) H. influenzae, M. catarrhalis (\u7279\u5225\u5728 COPD) Legionella (\u7279\u5225\u5728 elderly, smokers, \u2193 immunity, TNF inhibitors) Klebsiella & other GNR (\u7279\u5225\u5728 alcoholics & aspiration) Hospital-acquired or ventilator-assoc. (HAP/VAP) S. aureus, Pseudo., Klebsiella, E. coli, Enterobacter, Acinetobacter, Stenotrophomonas. IV abx w/in 90 d RF for MDR. Viral~ 20% cases (Chest 2017; 154:1) Immunosuppressed Above + PCP, fungi, Nocardia, non-TB mycobacteria (NTM), CMV Aspiration (NEJM 2019;380:651) Chemical pneumonitis due to aspiration of gastric contents Bacterial pneumonia \u226524\u201372 h after aspiration event outPt: oral flora (strep, S. aureus, anaerobes) inPt or chronically ill: GNR (Pseudomonas) and S. aureus","title":"Microbiology of Pneumonia"},{"location":"06-%E6%84%9F%E6%9F%93/06-01-Pneumonia/#clinical-manifestations","text":"Presenting features are variable and depend upon several host factors (esp. age) Classically: fever, cough w/ purulent sputum, consolidation on CXR Atypical pathogens (Legionella, Mycoplasma, Chlamydia, virus): historically classified as \u201catypical\u201d b/c they failed to grow on routine cx. Presentation varies from insidious to acute; imaging features vary from interstitial infiltrates to tree-in-bud opacities, to dense consolid. Clinical and imaging features do NOT distinguish \u201ctypical\u201d from \u201catypical\u201d Aspiration pneumonitis/PNA: can be infectious or non-infectious; may p/w acute inflammatory syndrome (fever, \u2191 WBC, etc.) or insidious course HAP/VAP: develops w/in 48 h after admission or mechanical ventilation, respectively","title":"Clinical manifestations"},{"location":"06-%E6%84%9F%E6%9F%93/06-01-Pneumonia/#diagnostic-studies","text":"Sputum Gram stain/Cx: reliable if high quality (ie, sputum not spit; <10 squamous cells/lpf) & if PNA should be purulent (>25 PMNs/lpf). Yield \u2193 >10 h after abx (CID 2014;58:1782). Blood cultures (before antibiotics!): \u2295 in ~10% of inPts, depending on pathogen Procalcitonin: \u2191 in acute bacterial (not viral) PNA. Consider stopping abx if levels <0.25 ng/ml (<0.5 ng/ml in ICU Pts) or \u2193 \u226580% from peak. \u2193 abx exposure by 2\u20133 d (Lancet ID 2016;16:819 & 2018;18:95). Not validated in immunocompromised hosts. Levels harder to interpret in CKD. False \u2295 in cardiac arrest, shock, surgery. CXR (PA & lateral; see Radiology inserts) \u2192 tap effusions if >5 cm or severe PNA Other: S a O 2 or P a O 2 , arterial pH (if severe), CBC w/ diff, Chem-20; HIV test (if unknown) Other micro based on clinical suspicion (paired serologies available for most atypicals): Mycoplasma: PCR of throat or sputum/BAL before first dose abx Legionella urinary Ag (detects L. pneumophila L1 serotype, 60\u201370% of clinical disease) S. pneumoniae urinary Ag (Se 70%, Sp >90%) MTb: (induced) sputum AFB stain \u00d73 q \u22658h (w/ \u22651 early morning specimen). Myco-bacterial cx (empiric respiratory isolation while pending); MTb DNA PCR if smear \u2295 Viral testing (DFA or PCR) on nasopharyngeal swab or sputum Bronchoscopy: consider if immunosupp., critically ill, failing to respond, VAP, suspected TB or PCP, or inadequate or \u0398 sputum cx. Some pathogens need specific cx media (eg, Legionella on BCYE). Reasons for failure to improve on initial Rx: Insufficient time: may take \u226572 h to see improvement (fever persists >4 d in ~20%) Insufficient drug levels for lung penetration (eg, vanco trough <15\u201320 \u00b5g/mL) Resistant organisms (or superinfxn): eg, MRSA, Pseudo.; consider bronchoscopy Wrong dx: fungal/viral, chemical pneumonitis, PE, CHF, ARDS, DAH, ILD; consider CT Parapneumonic effusion/empyema/abscess: if CXR \u0398, consider CT (dx tap \u00b1 chest tube if effusion present, esp. if loculated) Metastatic infection (eg, endocarditis, meningitis, septic arthritis)","title":"Diagnostic studies"},{"location":"06-%E6%84%9F%E6%9F%93/06-01-Pneumonia/#triage","text":"qSOFA predicts poor outcomes, prolonged ICU stay, and inhospital mortality if >2 of 3: RR>22, AMS, SBP<100 (JAMA 2016; 315:801) CURB-65: confusion, BUN >20, RR >30, BP <90/60, age >65 If score 0\u20131: Rx as outpt; 2: Rx as inpt; >3 consider ICU (Thorax 2013; 58:377)","title":"Triage"},{"location":"06-%E6%84%9F%E6%9F%93/06-01-Pneumonia/#treatment","text":"Scenario Regimen Special Considerations CAP (outPt) Azithro or doxy Avoid azithro/doxycycline if >25% resist- ance locally. Use FQ OR B-lactam + azithro/doxy. CAP (ward) Resp FQ or [3 rd -gen ceph + azithro] Doxycycline can replace azithro Omadacycline \u2248 FQ (NEJM 2019;380:517) CAP (ICU) Resp FQ + [3 rd -gen ceph or amp-sulbactam] Only cover MRSA or Pseudomonas if risk factors. If resp FQ contraindic., use azithro HCAP (incl. VAP) [Pip-tazo or cefepime or carbapen.] + [vanco or linezolid]395 May add resp FQ (or azithro) when concerned re: atypicals Aspiration Treat if abnl CXR (or if need to be intubated or develops septic shock) Amox-clav, amp-sulbactam, FQ, carbapenem If hosp-acquired and concern for multidrug-resistant pathogens: [pip-tazo, cefepime, or carbapenem] + [AG or colistin] Avoid quinolones if suspect TB Steroids: not standard practice, but appear to \u2193 mortality, mech vent, & ARDS (Cochrane 2017;12:CD007720). Consider in severe CAP (F i O 2 >0.5 + \u22651 of: pH<7.3; lactate >4; CRP >150). Avoid in suspected or known influenza. Dosing: pred 50 mg PO \u00d77 d or methylpred 0.5 mg/kg IV BID \u00d75 d. Duration: for CAP, 5 d if stable & afebrile for 48\u201372 h; for HAP/VAP, 8 d (CID 2017; 65:8) When possible, de-escalate abx based on sensitivities","title":"Treatment"},{"location":"06-%E6%84%9F%E6%9F%93/06-01-Pneumonia/#prognosis","text":"For low-risk Pts, can discharge immediately after switching to PO abx (CID 2007;44:S27) CXR resolves in most by 6 wk; consider f/u to r/o underlying malig (esp. if >50 y or smoker)","title":"Prognosis"},{"location":"06-%E6%84%9F%E6%9F%93/06-01-Pneumonia/#prevention","text":"All persons >65: give PCV13 vaccine followed by PPSV23 vaccine 1 y later. If PPSV23 already received, give PCV13. Age 19\u201364 w/ CHF/CMP, lung disease (including asthma), cirrhosis, DM, EtOH, or smoker: give PPSV23 Any age w/ immunocomp., CSF leak, cochlear implant, asplenia: give PCV13 followed by PPSV23 8 wks later. Smoking cessation counseling VAP precautions: HOB >30\u00b0, chlorhexidine rinse; aspiration precautions in high-risk Pts","title":"Prevention"},{"location":"06-%E6%84%9F%E6%9F%93/06-02-Fungal-Infections/","text":"","title":"06 02 Fungal Infections"},{"location":"06-%E6%84%9F%E6%9F%93/06-03-Infections-in-Immunosuppressed-Hosts/","text":"","title":"06 03 Infections in Immunosuppressed Hosts"},{"location":"06-%E6%84%9F%E6%9F%93/06-04-Urinary-Tract-Infections/","text":"add some new words","title":"06 04 Urinary Tract Infections"},{"location":"06-%E6%84%9F%E6%9F%93/06-05-Soft-Tissue-and-Bone-Infections/","text":"","title":"06 05 Soft Tissue and Bone Infections"},{"location":"06-%E6%84%9F%E6%9F%93/06-06-Infections-of-the-Nervous-System/","text":"","title":"06 06 Infections of the Nervous System"},{"location":"06-%E6%84%9F%E6%9F%93/06-07-Bacteremia-and-Endocarditis/","text":"","title":"06 07 Bacteremia and Endocarditis"},{"location":"06-%E6%84%9F%E6%9F%93/06-08-Tuberculosis/","text":"","title":"06 08 Tuberculosis"},{"location":"06-%E6%84%9F%E6%9F%93/06-09-HIV-AIDS/","text":"","title":"06 09 HIV AIDS"},{"location":"06-%E6%84%9F%E6%9F%93/06-10-Tick-Borne-Diseases/","text":"","title":"06 10 Tick Borne Diseases"},{"location":"06-%E6%84%9F%E6%9F%93/06-11-Fever-Syndromes/","text":"","title":"06 11 Fever Syndromes"},{"location":"07-%E5%85%A7%E5%88%86%E6%B3%8C/07-01-Pituitary-Disorders/","text":"","title":"07 01 Pituitary Disorders"},{"location":"07-%E5%85%A7%E5%88%86%E6%B3%8C/07-02.Thyroid-Disorders/","text":"","title":"07 02.Thyroid Disorders"},{"location":"07-%E5%85%A7%E5%88%86%E6%B3%8C/07-03-Adrenal-Disorders/","text":"","title":"07 03 Adrenal Disorders"},{"location":"07-%E5%85%A7%E5%88%86%E6%B3%8C/07-04-Calcium-Disorders/","text":"","title":"07 04 Calcium Disorders"},{"location":"07-%E5%85%A7%E5%88%86%E6%B3%8C/07-05-Diabetes-Mellitus/","text":"","title":"07 05 Diabetes Mellitus"},{"location":"07-%E5%85%A7%E5%88%86%E6%B3%8C/07-06-Lipid-Disorders/","text":"","title":"07 06 Lipid Disorders"},{"location":"08-%E9%A2%A8%E5%85%8D/08-01-Approach-to-Rheumatic-Disease/","text":"","title":"08 01 Approach to Rheumatic Disease"},{"location":"08-%E9%A2%A8%E5%85%8D/08-02-Rheumatoid-Arthritis/","text":"","title":"08 02 Rheumatoid Arthritis"},{"location":"08-%E9%A2%A8%E5%85%8D/08-03-Adult-Onset-Still%E2%80%99s-Disease-and-Relapsing-Polychondritis/","text":"","title":"08 03 Adult Onset Still\u2019s Disease and Relapsing Polychondritis"},{"location":"08-%E9%A2%A8%E5%85%8D/08-04-Crystal-Deposition-Arthritides/","text":"","title":"08 04 Crystal Deposition Arthritides"},{"location":"08-%E9%A2%A8%E5%85%8D/08-05-Seronegative-Spondyloarthritis/","text":"","title":"08 05 Seronegative Spondyloarthritis"},{"location":"08-%E9%A2%A8%E5%85%8D/08-06-Infectious-Arthritis-and-Bursitis/","text":"","title":"08 06 Infectious Arthritis and Bursitis"},{"location":"08-%E9%A2%A8%E5%85%8D/08-07-Connective-Tissue-Diseases/","text":"","title":"08 07 Connective Tissue Diseases"},{"location":"08-%E9%A2%A8%E5%85%8D/08-08-Systemic-Lupus-Erythematosus/","text":"","title":"08 08 Systemic Lupus Erythematosus"},{"location":"08-%E9%A2%A8%E5%85%8D/08-09-Vasculitis/","text":"","title":"08 09 Vasculitis"},{"location":"08-%E9%A2%A8%E5%85%8D/08-10-IgG4-Related-Disease/","text":"","title":"08 10 IgG4 Related Disease"},{"location":"08-%E9%A2%A8%E5%85%8D/08-11-Cryoglobulinemia/","text":"","title":"08 11 Cryoglobulinemia"},{"location":"08-%E9%A2%A8%E5%85%8D/08-12-Amyloidosis/","text":"","title":"08 12 Amyloidosis"},{"location":"09-%E7%A5%9E%E5%85%A7/09-01-Change-in-Mental-Status/","text":"","title":"09 01 Change in Mental Status"},{"location":"09-%E7%A5%9E%E5%85%A7/09-02-Seizures/","text":"","title":"09 02 Seizures"},{"location":"09-%E7%A5%9E%E5%85%A7/09-03-Alcohol-Withdrawal/","text":"","title":"09 03 Alcohol Withdrawal"},{"location":"09-%E7%A5%9E%E5%85%A7/09-04-Dizziness/","text":"","title":"09 04 Dizziness"},{"location":"09-%E7%A5%9E%E5%85%A7/09-05-Stroke/","text":"","title":"09 05 Stroke"},{"location":"09-%E7%A5%9E%E5%85%A7/09-06-Weakness-and-Neuromuscular-Dysfunction/","text":"","title":"09 06 Weakness and Neuromuscular Dysfunction"},{"location":"09-%E7%A5%9E%E5%85%A7/09-07-Headache/","text":"","title":"09 07 Headache"},{"location":"09-%E7%A5%9E%E5%85%A7/09-08-Back-and-Spinal-Cord-Disease/","text":"","title":"09 08 Back and Spinal Cord Disease"},{"location":"10-%E6%80%A5%E9%87%8D/1.%20%E6%80%A5%E9%87%8D/","text":"\u6025\u91cd","title":"\u6025\u91cd"},{"location":"10-%E6%80%A5%E9%87%8D/1.%20%E6%80%A5%E9%87%8D/#_1","text":"","title":"\u6025\u91cd"}]}